Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

Blood

Volumn 103, Issue 2, 2004, Pages 435-441

  Blaise, Didier ^a   Bay, Jacques Olivier ^b   Faucher, Catherine ^b   Michallet, Mauricette ^b   Boiron, Jean Michel ^b   Choufi, Bachra ^b   Cahn, Jean Yves ^b   Gratecos, Nicole ^b   Sotto, Jean Jacques ^b   François, Sylvie ^b   Fleury, Joel ^b   Mohty, Mohamad ^b   Chabannon, Christian ^b   Bilger, Karin ^b   Gravis, Gwenaelle ^b   Viret, Frédéric ^b   Braud, Anne Chantal ^b   Bardou, Valérie Jeanne ^b   Maraninchi, Dominique ^b   Viens, Patrice ^b  

^a INSTITUT PAOLI CALMETTES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE PHOSPHATE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CARCINOMA; CHIMERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORTALITY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE;

EID: 9144236207     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2236     Document Type: Article

References (38)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
3. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175-178.
4. Marmont AM, Horowitz MM, Gale RP, et al, T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
5. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501-1508.
6. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet. 1996;348:1242-1243.
7. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986-993.
8. Or R, Ackerstein A, Nagler A, Kapelushnik J, et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol Ther. 1998;4:1-6.
9. Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant. 2002;30:813-831.
10. Rosenberg SA. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J Clin. 1999;49:70-73,65.
11. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451-6458.
12. Morecki S, Moshel Y, Gelfend Y, Pugatsch T, Slavin S. Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer. 1997;71:59-63.
13. Bay JO, Choufi B, Pomel C, et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant. 2000;25:681-682.
14. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
15. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
16. Storb R. Non-myeloablative preparative regimens: experimental data and clinical practice. J Clin Oncol. 1998:241-249.
17. Bay JO, Fleury J, Choufi B, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. 2002;30:95-102.
18. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstimprimed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537-546.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
20. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-259.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. Mohty M, Fegueux N, Exbrayat C, et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic, transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant. 2001;28:335-339.
23. Kwiatkowski F, Girard M, Hacene K, Berlie J. [Sem: a suitable statistical software adapted for research in oncology]. Bull Cancer. 2000;87:715-721.
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1957;53:457-481.
26. Cox D. Regression models and life tables. J R Stat Soc (B). 1972;34:187-220.
27. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant. 2000;26:251-255.
28. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102:470-476.
29. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175-181.
30. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood. 2002;100:3128-3134.
31. Ueno NT, Hortobagyi GN, Champlin RE. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. Cancer Treat Res. 1999;101:133-156.
32. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99:4234-4236.
33. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
34. Négrier S, Escudier B, Lasset C, et al, d'Immunothérapie ftGF. Recombinant human interleukin 2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998;338;1272-1278.
35. Childs R, Bradstock K, Gottlieb D, et al. Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: non durable chemotherapy responses without clinically meaningful grafts-vs-tumor (GVT) effects [abstract]. Blood. 2002;100:429a.
36. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115-122.
37. Phan G, Yang J, Sherry R, et al. Cancer regression and autoImmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377.
38. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 1995;25:340-347.